A trailblazing drug that has positive potential to be a breakthrough in reversing ageing and a pharmaceutical agent in cancer-related issues as follows:
- anti-rejection drug that works after an organ transplant,
- a drug that keeps renal failure obsolete,
- a drug that cures patients with rare lung disease,
- a drug that protects coronary stents,
- a drug that promotes tumor regression,
- a drug that cures facial angiofibromas,
- a drug that has a high potential to increase longevity by combating diseases like Alzheimer,
- a drug that is a potential cure for muscular dystrophy,
- a drug that develop resistance to immunosuppressant drugs.
This amazing formula is called ‘Rapamycin,’ also called ‘Sirolimus.’ In the pharmacology market Rapamycin is called ‘Rapamune.’ Touting the benefits of this drug is Dr. Mikhail Blagosklonny, a present professor and contributing scientist of Oncology at the Roswell Park Cancer Institute in Buffalo, New York.In addition to his professorship in Oncology and its many medical branches, he is a renowned physician, scientist, researcher, and author. To his credit, he has published hundreds of medical reviews, research articles, papers and has attributed to thousands of publication citations. To support his publication prowess, Dr. Blagosklonny holds an h-index of 83 which is the number of cited papers that is published and recognized by peer publications.
Dr. Blagosklonny is now the Editor-in-Chief of ‘Oncotarget’ which is a leading, twice a week publication on oncology issues that is published online and in other media formats. He is also the journals contributing editor and submitter of cancer findings and articles. Blagosklonny is the Editor-in-Chief of ‘Cell Cycle’ which is a bi-weekly peer-reviewed journal of high priority research from all areas of cellular biology.Dr. Blagosklonny is also a citation contributing editor of journals highlighting findings and theories of research and clinical scientists. The journals, to name a few, include the Cell Death and Differentiation, Cancer Biology/Therapy, the Autophagy Journal, and the International Journal of Cancer.
Mikhail (Misha) V. Blagosklonny, M.D., Ph.D., graduated with a degree in Internal Medicine and a PhD in Experimental Medicine and Cardiology from the prestigious First Pavlov State Medical University of St. Petersburg, Russia. Much of his studies at First Pavlov involved cancer modalities, including Biogerontology or anti-aging research and theories, among which involves molecular damage that he believes contributes to growing older.Prior to Dr. Blagosklonny’s appointment to Roswell Park Cancer Institute, he advanced in different medical career advancements, including Associate Professor of Medicine at New York Medical College in Valhalla, New York. He was also one of the head scientists at the Ordway Research Institute, Albany, New York, which was his gateway to Roswell.With the advanced tools and vigorous channels supported by Dr. Blagosklonny in the field of cancer cellular research, simply put Mikhail believes that cancer can be cured, which is why he adamantly believes in Rapamycin to give humanity a disease-free life.